Company intelligence / Profile preview

1DROP Diagnostics

Switzerland

Ownership: Private
Development stage: Other

Overview

1DROP has developed a commercial point-of-care diagnostic platform that delivers laboratory-quality results from a single drop of blood. The system uses capillary-driven microfluidic chips to automatically detect multiple biomarkers including proteins, nucleic acids, and peptides. Their technology received FDA Emergency Use Authorization (EUA) in May 2020 for the 1copy COVID-19 qPCR Multi Kit.

Therapeutic areas: ImmunologyNephrologyCardiovascularEndocrinology
Modalities: DeviceDiagnostic test
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on 1DROP Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1DROP Diagnostics.

Explore the full profile